Anixa Biosciences Reports Positive Survival Data from Lira-cel Trial
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 11 2026
0mins
Source: PRnewswire
- Extended Survival Rates: Anixa's lira-cel clinical trial has shown that several patients have survived significantly beyond the expected median survival, with one patient living for 28 months, indicating the therapy's potential to transform treatment outcomes for recurrent ovarian cancer patients.
- Clinical Trial Updates: Data presented on May 7, 2026, at the ISCT Annual Meeting highlighted lira-cel's favorable safety profile, with no dose-limiting toxicities observed, supporting ongoing dose escalation and clinical evaluation efforts.
- Optimized Treatment Protocol: Anixa plans to evaluate a dose approximately three times higher in the next cohort, incorporating lymphodepletion with cyclophosphamide and fludarabine, aiming to create a more favorable environment for CAR-T cell expansion and persistence, thereby enhancing therapeutic efficacy.
- Unique Target Advantage: Lira-cel targets the follicle-stimulating hormone receptor (FSHR), selectively expressed on ovarian cells, representing a novel CAR-T target that may provide new treatment options for recurrent ovarian cancer patients, thereby strengthening Anixa's competitive position in the biotechnology sector.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ANIX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ANIX
Wall Street analysts forecast ANIX stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 2.750
Low
10.00
Averages
10.00
High
10.00
Current: 2.750
Low
10.00
Averages
10.00
High
10.00
No data
About ANIX
Anixa Biosciences, Inc. is a biotechnology company. The Company is developing therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics program consists of the development of liraltagene autoleucel (lira-cel), a chimeric endocrine receptor-T cell therapy, which is a novel form of chimeric antigen receptor-T cell (CAR-T) technology, initially focused on treating ovarian cancer, that is being developed of its subsidiary, Certainty Therapeutics, Inc. (Certainty). Its vaccine programs include the development of a vaccine against breast cancer, the development of a vaccine against ovarian cancer, and a vaccine discovery program utilizing the same mechanism of its breast and ovarian cancer vaccines to develop additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon and prostate. It is also developing a method to vaccinate women against breast cancer, focused on triple-negative breast cancer.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Anixa Biosciences Reports Positive Survival Data from Lira-cel Trial
- Extended Survival Rates: Anixa's lira-cel clinical trial has shown that several patients have survived significantly beyond the expected median survival, with one patient living for 28 months, indicating the therapy's potential to transform treatment outcomes for recurrent ovarian cancer patients.
- Clinical Trial Updates: Data presented on May 7, 2026, at the ISCT Annual Meeting highlighted lira-cel's favorable safety profile, with no dose-limiting toxicities observed, supporting ongoing dose escalation and clinical evaluation efforts.
- Optimized Treatment Protocol: Anixa plans to evaluate a dose approximately three times higher in the next cohort, incorporating lymphodepletion with cyclophosphamide and fludarabine, aiming to create a more favorable environment for CAR-T cell expansion and persistence, thereby enhancing therapeutic efficacy.
- Unique Target Advantage: Lira-cel targets the follicle-stimulating hormone receptor (FSHR), selectively expressed on ovarian cells, representing a novel CAR-T target that may provide new treatment options for recurrent ovarian cancer patients, thereby strengthening Anixa's competitive position in the biotechnology sector.
See More
Anixa Biosciences CEO to Appear on Bloomberg Interview
- Clinical Trial Progress: Anixa Biosciences' breast cancer vaccine achieved primary endpoints with 74% of participants generating protocol-defined immune responses in its recently completed Phase 1 trial, which not only demonstrates the vaccine's efficacy but also lays the groundwork for subsequent Phase 2 trials, potentially enhancing the company's market competitiveness in cancer treatment.
- CAR-T Therapy Data: The company's ovarian cancer CAR-T therapy, lira-cel, has shown positive survival data in its ongoing Phase 1 clinical trial, which not only boosts investor confidence in Anixa but may also attract more partners for further development, driving innovation in cancer immunotherapy.
- Media Exposure Opportunity: Anixa's Chairman and CEO, Dr. Amit Kumar, will be interviewed on Bloomberg TV's RedChip Small Stocks, Big Money™ show on May 2, expected to reach approximately 73 million households, which will help enhance the company's brand visibility and attract potential investors.
- Partnerships: Anixa's collaboration with Cleveland Clinic to develop breast and ovarian cancer vaccines showcases its unique business model, allowing the company to continuously explore emerging technologies and drive the commercialization of cancer treatments through partnerships with world-renowned research institutions.
See More
Anixa Biosciences CEO to Appear on Bloomberg Interview
- Clinical Trial Progress: Anixa Biosciences' breast cancer vaccine achieved primary endpoints in its recently completed Phase 1 clinical trial, generating protocol-defined immune responses in 74% of participants, which not only demonstrates the vaccine's efficacy but also lays the groundwork for subsequent Phase 2 trials.
- CAR-T Therapy Data: The company's ovarian cancer CAR-T therapy, lira-cel, exhibited positive survival data in its ongoing Phase 1 clinical trial, which could attract more investor interest and further enhance the company's market valuation.
- Media Exposure Opportunity: Anixa's Chairman and CEO, Amit Kumar, will be interviewed on Bloomberg TV's RedChip Small Stocks, Big Money™ show, airing on May 2 at 7 PM ET, which is expected to boost the company's visibility among investors.
- Collaborative R&D Model: Anixa's partnerships with renowned research institutions like Cleveland Clinic and Moffitt Cancer Center ensure its technological leadership in cancer immunotherapy, while continuously exploring emerging technologies for commercialization enhances the company's competitive edge in the market.
See More
Anixa Biosciences Secures New Patent for Breast Cancer Vaccine
- Global IP Expansion: Anixa Biosciences has secured Patent Number 432748 from the Mexican Institute of Industrial Property, covering key aspects of its breast cancer vaccine technology, ensuring IP protection in Mexico until 2040, thereby enhancing its competitive edge in the global market.
- Clinical Development Progress: The vaccine's clinical development in the U.S. continues, with Phase 1 trial results indicating that 74% of participants exhibited expected immune responses across all tested doses, demonstrating safety and tolerability, which lays the groundwork for the upcoming Phase 2 clinical trial.
- Strategic Collaboration Advantage: Developed in partnership with Cleveland Clinic, the vaccine employs an immunization strategy against human α-lactalbumin, aiming to selectively prime the immune system to prevent tumor formation, showcasing its innovative potential in breast cancer treatment.
- Strengthened IP Portfolio: The issuance of this patent further solidifies Anixa's intellectual property portfolio, establishing a foundation for future international development and commercialization strategies, indicating the company's long-term growth potential in the global breast cancer vaccine market.
See More
Anixa Biosciences Secures New Patent for Breast Cancer Vaccine
- Global IP Expansion: Anixa Biosciences has secured Patent Number 432748 from the Mexican Institute of Industrial Property, covering its breast cancer vaccine technology with protection extending to 2040, thereby enhancing its competitive edge in international markets.
- Clinical Development Progress: The vaccine continues its clinical development in the U.S., with positive Phase 1 results indicating that 74% of participants across all doses elicited expected immune responses, demonstrating good safety and tolerability.
- Strategic Partnership Advantage: Anixa's exclusive licensing of the vaccine technology from Cleveland Clinic, combined with its broad intellectual property portfolio, enhances its potential for partnerships with larger pharmaceutical companies, facilitating global commercialization efforts.
- Future Development Plans: By reinforcing its global patent estate, Anixa lays the groundwork for future international development and commercialization strategies, aiming to capitalize on market opportunities in regions with high breast cancer incidence, thereby boosting the company's long-term growth potential.
See More
Anixa Biosciences Reports Positive Phase 1 Trial Data for Lira-cel
- Clinical Trial Progress: Anixa Biosciences' ongoing Phase 1 trial of lira-cel demonstrates positive survival data, highlighting its potential in treating recurrent ovarian cancer, which is expected to enhance the company's market position in cancer therapeutics.
- International Conference Presentation: Operations Director Cheryl Cox will present the clinical trial design and objectives at the 2026 International Society for Cell & Gene Therapy Annual Meeting, likely attracting global expert attention and further elevating Anixa's industry influence.
- Technological Innovation: Lira-cel employs a unique CAR-T technology that specifically targets the follicle-stimulating hormone receptor (FSHR) on ovarian cells, potentially providing new treatment options for recurrent ovarian cancer patients, thereby strengthening Anixa's product competitiveness.
- Strategic Partnerships: Anixa's collaboration with Moffitt Cancer Center for the development of lira-cel leverages the center's leadership in cancer immunotherapy, indicating the company's strategic focus on technology development and market penetration aimed at accelerating product commercialization.
See More
Anixa Biosciences Reports Positive Survival Data from Lira-cel Trial
- Extended Survival Rates: Anixa's lira-cel clinical trial has shown that several patients have survived significantly beyond the expected median survival, with one patient living for 28 months, indicating the therapy's potential to transform treatment outcomes for recurrent ovarian cancer patients.
- Clinical Trial Updates: Data presented on May 7, 2026, at the ISCT Annual Meeting highlighted lira-cel's favorable safety profile, with no dose-limiting toxicities observed, supporting ongoing dose escalation and clinical evaluation efforts.
- Optimized Treatment Protocol: Anixa plans to evaluate a dose approximately three times higher in the next cohort, incorporating lymphodepletion with cyclophosphamide and fludarabine, aiming to create a more favorable environment for CAR-T cell expansion and persistence, thereby enhancing therapeutic efficacy.
- Unique Target Advantage: Lira-cel targets the follicle-stimulating hormone receptor (FSHR), selectively expressed on ovarian cells, representing a novel CAR-T target that may provide new treatment options for recurrent ovarian cancer patients, thereby strengthening Anixa's competitive position in the biotechnology sector.
See More
Anixa Biosciences CEO to Appear on Bloomberg Interview
- Clinical Trial Progress: Anixa Biosciences' breast cancer vaccine achieved primary endpoints with 74% of participants generating protocol-defined immune responses in its recently completed Phase 1 trial, which not only demonstrates the vaccine's efficacy but also lays the groundwork for subsequent Phase 2 trials, potentially enhancing the company's market competitiveness in cancer treatment.
- CAR-T Therapy Data: The company's ovarian cancer CAR-T therapy, lira-cel, has shown positive survival data in its ongoing Phase 1 clinical trial, which not only boosts investor confidence in Anixa but may also attract more partners for further development, driving innovation in cancer immunotherapy.
- Media Exposure Opportunity: Anixa's Chairman and CEO, Dr. Amit Kumar, will be interviewed on Bloomberg TV's RedChip Small Stocks, Big Money™ show on May 2, expected to reach approximately 73 million households, which will help enhance the company's brand visibility and attract potential investors.
- Partnerships: Anixa's collaboration with Cleveland Clinic to develop breast and ovarian cancer vaccines showcases its unique business model, allowing the company to continuously explore emerging technologies and drive the commercialization of cancer treatments through partnerships with world-renowned research institutions.
See More
Anixa Biosciences CEO to Appear on Bloomberg Interview
- Clinical Trial Progress: Anixa Biosciences' breast cancer vaccine achieved primary endpoints in its recently completed Phase 1 clinical trial, generating protocol-defined immune responses in 74% of participants, which not only demonstrates the vaccine's efficacy but also lays the groundwork for subsequent Phase 2 trials.
- CAR-T Therapy Data: The company's ovarian cancer CAR-T therapy, lira-cel, exhibited positive survival data in its ongoing Phase 1 clinical trial, which could attract more investor interest and further enhance the company's market valuation.
- Media Exposure Opportunity: Anixa's Chairman and CEO, Amit Kumar, will be interviewed on Bloomberg TV's RedChip Small Stocks, Big Money™ show, airing on May 2 at 7 PM ET, which is expected to boost the company's visibility among investors.
- Collaborative R&D Model: Anixa's partnerships with renowned research institutions like Cleveland Clinic and Moffitt Cancer Center ensure its technological leadership in cancer immunotherapy, while continuously exploring emerging technologies for commercialization enhances the company's competitive edge in the market.
See More
Anixa Biosciences Secures New Patent for Breast Cancer Vaccine
- Global IP Expansion: Anixa Biosciences has secured Patent Number 432748 from the Mexican Institute of Industrial Property, covering key aspects of its breast cancer vaccine technology, ensuring IP protection in Mexico until 2040, thereby enhancing its competitive edge in the global market.
- Clinical Development Progress: The vaccine's clinical development in the U.S. continues, with Phase 1 trial results indicating that 74% of participants exhibited expected immune responses across all tested doses, demonstrating safety and tolerability, which lays the groundwork for the upcoming Phase 2 clinical trial.
- Strategic Collaboration Advantage: Developed in partnership with Cleveland Clinic, the vaccine employs an immunization strategy against human α-lactalbumin, aiming to selectively prime the immune system to prevent tumor formation, showcasing its innovative potential in breast cancer treatment.
- Strengthened IP Portfolio: The issuance of this patent further solidifies Anixa's intellectual property portfolio, establishing a foundation for future international development and commercialization strategies, indicating the company's long-term growth potential in the global breast cancer vaccine market.
See More
Anixa Biosciences Secures New Patent for Breast Cancer Vaccine
- Global IP Expansion: Anixa Biosciences has secured Patent Number 432748 from the Mexican Institute of Industrial Property, covering its breast cancer vaccine technology with protection extending to 2040, thereby enhancing its competitive edge in international markets.
- Clinical Development Progress: The vaccine continues its clinical development in the U.S., with positive Phase 1 results indicating that 74% of participants across all doses elicited expected immune responses, demonstrating good safety and tolerability.
- Strategic Partnership Advantage: Anixa's exclusive licensing of the vaccine technology from Cleveland Clinic, combined with its broad intellectual property portfolio, enhances its potential for partnerships with larger pharmaceutical companies, facilitating global commercialization efforts.
- Future Development Plans: By reinforcing its global patent estate, Anixa lays the groundwork for future international development and commercialization strategies, aiming to capitalize on market opportunities in regions with high breast cancer incidence, thereby boosting the company's long-term growth potential.
See More
Anixa Biosciences Reports Positive Phase 1 Trial Data for Lira-cel
- Clinical Trial Progress: Anixa Biosciences' ongoing Phase 1 trial of lira-cel demonstrates positive survival data, highlighting its potential in treating recurrent ovarian cancer, which is expected to enhance the company's market position in cancer therapeutics.
- International Conference Presentation: Operations Director Cheryl Cox will present the clinical trial design and objectives at the 2026 International Society for Cell & Gene Therapy Annual Meeting, likely attracting global expert attention and further elevating Anixa's industry influence.
- Technological Innovation: Lira-cel employs a unique CAR-T technology that specifically targets the follicle-stimulating hormone receptor (FSHR) on ovarian cells, potentially providing new treatment options for recurrent ovarian cancer patients, thereby strengthening Anixa's product competitiveness.
- Strategic Partnerships: Anixa's collaboration with Moffitt Cancer Center for the development of lira-cel leverages the center's leadership in cancer immunotherapy, indicating the company's strategic focus on technology development and market penetration aimed at accelerating product commercialization.
See More
